What You Should Know:
– Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC).
– The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.
Challenges in ESR1 Testing
ESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression.
Tempus Next: Guiding Clinical Decisions
Tempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression. These timely notifications, delivered directly into the physician’s workflow, will help ensure that patients receive the appropriate testing and that treatment decisions are informed by the latest genomic information.
“This collaboration is the first time we are applying Tempus Next to address a critical care gap in breast cancer, leveraging AI to support physicians in delivering recent guideline recommendations for this specific patient population,” said Chris Scotto DiVetta, Senior Vice President, AI Applications at Tempus. “We have just begun to demonstrate the potential Next can have in helping physicians deliver the most up-to-date, guideline-recommended care for their patients across a number of indications, and we look forward to making that a reality for patients with metastatic breast cancer.”
